医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2015年
4期
32-33
,共2页
急性脑梗死%认知功能障碍%神经节苷脂%奥拉西坦
急性腦梗死%認知功能障礙%神經節苷脂%奧拉西坦
급성뇌경사%인지공능장애%신경절감지%오랍서탄
Acute cerebral infarction%Cognitive dysfunction%Ganglioside%Olathe temple
目的::观察神经节苷脂联合奥拉西坦治疗急性脑梗死患者认知障碍的临床疗效。方法:将92例急性脑梗死伴有认知功能障碍的患者随机分为两组:治疗组和对照组。两组在一般治疗的基础上,对照组加用奥拉西坦注射液静脉滴注,1次/d;观察组在对照组基础上联合神经节苷脂注射液,1次/d。两组治疗时间均为14d。观察患者治疗前后简易智能状态量表评分(MMSE)及日常生活活动能力(ADL)量表(Barthel指数)。结果:治疗后,治疗组和对照组患者的MMSE评分及ADL评分均较治疗前升高(P<0.05),且治疗组与对照组组间比较,差异具有统计学意义(P<0.05)。结论:神经节苷脂联合奥拉西坦能明显改善急性脑梗死患者的认知功能状态,提高患者的日常生活活动能力,值得临床进一步探索应用。
目的::觀察神經節苷脂聯閤奧拉西坦治療急性腦梗死患者認知障礙的臨床療效。方法:將92例急性腦梗死伴有認知功能障礙的患者隨機分為兩組:治療組和對照組。兩組在一般治療的基礎上,對照組加用奧拉西坦註射液靜脈滴註,1次/d;觀察組在對照組基礎上聯閤神經節苷脂註射液,1次/d。兩組治療時間均為14d。觀察患者治療前後簡易智能狀態量錶評分(MMSE)及日常生活活動能力(ADL)量錶(Barthel指數)。結果:治療後,治療組和對照組患者的MMSE評分及ADL評分均較治療前升高(P<0.05),且治療組與對照組組間比較,差異具有統計學意義(P<0.05)。結論:神經節苷脂聯閤奧拉西坦能明顯改善急性腦梗死患者的認知功能狀態,提高患者的日常生活活動能力,值得臨床進一步探索應用。
목적::관찰신경절감지연합오랍서탄치료급성뇌경사환자인지장애적림상료효。방법:장92례급성뇌경사반유인지공능장애적환자수궤분위량조:치료조화대조조。량조재일반치료적기출상,대조조가용오랍서탄주사액정맥적주,1차/d;관찰조재대조조기출상연합신경절감지주사액,1차/d。량조치료시간균위14d。관찰환자치료전후간역지능상태량표평분(MMSE)급일상생활활동능력(ADL)량표(Barthel지수)。결과:치료후,치료조화대조조환자적MMSE평분급ADL평분균교치료전승고(P<0.05),차치료조여대조조조간비교,차이구유통계학의의(P<0.05)。결론:신경절감지연합오랍서탄능명현개선급성뇌경사환자적인지공능상태,제고환자적일상생활활동능력,치득림상진일보탐색응용。
ObjectiveObserve the ganglioside joint olathe treatment the curative effect of cognitive impairment in patients with acute cerebral infarction.Methods 92 cases of acute cerebral infarction with cognitive dysfunction patients randomly divided into two groups: treatment group and control group. The control group used olathe injection intravenous drip, 1 / d; Observation group in the control group on the basis of joint ganglioside injection, 1 / d.Results After treatment, the treatment group and control group in patients with MMSE scores and ADL scores are higher than before treatment (P < 0.05), statistically significant difference (P < 0.05).Conclusions Ganglioside joint olathe temple can significantly improve cognitive function in patients with acute cerebral infarction, improve patients' daily life activities ability, to further explore the clinical application.